Foundation Medicine, a precision medicine company focused on cancer care, has announced a strategic partnership with Manifold, an artificial intelligence data platform for life sciences, to enhance its FoundationInsights® platform with advanced AI capabilities. The collaboration aims to accelerate drug discovery and development by providing more intuitive and faster access to genomic insights.
Enhanced AI Capabilities Transform Data Analytics
The enhanced version of FoundationInsights® leverages Manifold's AI data platform to offer a more streamlined approach to extracting insights from Foundation Medicine's proprietary dataset, which contains de-identified genomic results from more than 800,000 patients. The platform now features AI-enabled natural language searches that allow users to easily set complex genomic criteria without requiring extensive technical expertise.
"Foundation Medicine is using AI and machine learning to power our real-world data solutions to accelerate drug discovery and development," said Troy Schurr, chief biopharma business officer at Foundation Medicine. "With new AI-powered capabilities from Manifold, biopharmaceutical partners can find the answers needed to make decisions faster than ever before."
Comprehensive Analytics for Drug Development
The platform provides users with the ability to rapidly identify groups of patients and explore the prevalence of genomic alterations. For researchers requiring deeper analysis, technical users can perform in-depth, customized analyses using popular programming languages such as Python and R. This dual approach ensures accessibility for both clinical researchers and data scientists.
Vinay Seth Mohta, chief executive officer and co-founder at Manifold, emphasized the significance of the collaboration: "By combining Foundation Medicine's powerful multimodal databases with Manifold's purpose-built AI capabilities for life sciences, together we can make it easier for researchers to work smarter and faster to unlock the answers needed to discover innovative personalized therapies."
Market Availability and Future Plans
The AI-powered FoundationInsights® platform is now available to biopharmaceutical partners, providing what Schurr describes as "a one-stop shop to easily access comprehensive multimodal data from Foundation Medicine combined with advanced analytics and visualization tools." The companies plan to launch a customized version specifically designed for healthcare providers and health systems in 2026.
Manifold brings significant expertise to the partnership as the operator and maintainer of Terra, described as the leading open platform for science at scale. The company specializes in accelerating analytic workflows with multimodal biomedical data, reducing processing times from months to minutes while enabling governed collaboration between companies, teams, and AI agents.
